Natera (NASDAQ:NTRA) Given New $150.00 Price Target at Leerink Partners

Natera (NASDAQ:NTRA) had its target price increased by Leerink Partners from $140.00 to $150.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

Other equities analysts also recently issued research reports about the company. Piper Sandler reiterated an “overweight” rating and set a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. The Goldman Sachs Group increased their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday. Stephens restated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Canaccord Genuity Group increased their target price on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Robert W. Baird boosted their price target on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $124.44.

Natera Stock Performance

Shares of Natera stock opened at $122.35 on Thursday. Natera has a one year low of $36.90 and a one year high of $133.54. The company has a market cap of $15.02 billion, a price-to-earnings ratio of -39.21 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The business’s 50 day moving average price is $123.15 and its 200 day moving average price is $110.16.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter last year, the business posted ($0.97) earnings per share. The firm’s revenue was up 58.1% compared to the same quarter last year. On average, research analysts predict that Natera will post -1.96 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 2,638 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $277,412.08. Following the completion of the transaction, the chief executive officer now owns 210,377 shares in the company, valued at $22,123,245.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Natera news, CEO Steven Leonard Chapman sold 2,638 shares of the firm’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total value of $277,412.08. Following the sale, the chief executive officer now directly owns 210,377 shares in the company, valued at $22,123,245.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Sheena sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $125.67, for a total value of $377,010.00. Following the sale, the insider now owns 57,432 shares of the company’s stock, valued at approximately $7,217,479.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,765 shares of company stock valued at $6,016,700 in the last quarter. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the second quarter worth about $28,000. Quarry LP grew its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the period. Tobam purchased a new stake in Natera in the second quarter valued at approximately $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Natera in the first quarter valued at approximately $83,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.